CO5160246A1 - Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias - Google Patents

Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias

Info

Publication number
CO5160246A1
CO5160246A1 CO00006605A CO00006605A CO5160246A1 CO 5160246 A1 CO5160246 A1 CO 5160246A1 CO 00006605 A CO00006605 A CO 00006605A CO 00006605 A CO00006605 A CO 00006605A CO 5160246 A1 CO5160246 A1 CO 5160246A1
Authority
CO
Colombia
Prior art keywords
prevention
reduction
coronary
approximately
coronary interventions
Prior art date
Application number
CO00006605A
Other languages
English (en)
Spanish (es)
Inventor
Jeffrey R Granett
H Shusterman Neil
Prichard David C U
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5160246A1 publication Critical patent/CO5160246A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CO00006605A 1999-02-03 2000-02-03 Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias CO5160246A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11846399P 1999-02-03 1999-02-03

Publications (1)

Publication Number Publication Date
CO5160246A1 true CO5160246A1 (es) 2002-05-30

Family

ID=22378760

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00006605A CO5160246A1 (es) 1999-02-03 2000-02-03 Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias

Country Status (17)

Country Link
EP (1) EP1180027A4 (no)
JP (1) JP2002536326A (no)
KR (1) KR20010101933A (no)
CN (1) CN1338930A (no)
AR (1) AR022475A1 (no)
AU (1) AU2978500A (no)
BR (1) BR0007901A (no)
CA (1) CA2361578A1 (no)
CO (1) CO5160246A1 (no)
HU (1) HUP0200148A3 (no)
IL (1) IL144719A0 (no)
MX (1) MXPA01007833A (no)
NO (1) NO20013789L (no)
PL (1) PL349926A1 (no)
TR (1) TR200102262T2 (no)
WO (1) WO2000045810A1 (no)
ZA (1) ZA200106297B (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097650B2 (en) * 2005-07-27 2012-01-17 The Trustees Of Columbia University In The City Of New York Method of treating a condition associated with phosphorylation of TASK-1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2617407B2 (ja) * 1992-09-14 1997-06-04 キッセイ薬品工業株式会社 血管内膜細胞過剰増殖疾患の予防および治療剤
KR19990044478A (ko) * 1995-09-07 1999-06-25 간자와 무츠와 2-아실아미노벤즈아미드 유도체 및 혈관내막세포 과잉증식에 기인하는 질환의 예방 및 치료제
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention

Also Published As

Publication number Publication date
EP1180027A1 (en) 2002-02-20
EP1180027A4 (en) 2004-11-17
ZA200106297B (en) 2002-07-31
HUP0200148A3 (en) 2003-06-30
AR022475A1 (es) 2002-09-04
AU2978500A (en) 2000-08-25
PL349926A1 (en) 2002-10-21
MXPA01007833A (es) 2002-06-21
NO20013789D0 (no) 2001-08-02
IL144719A0 (en) 2002-06-30
NO20013789L (no) 2001-09-28
BR0007901A (pt) 2001-10-30
KR20010101933A (ko) 2001-11-15
HUP0200148A2 (hu) 2002-05-29
CA2361578A1 (en) 2000-08-10
CN1338930A (zh) 2002-03-06
TR200102262T2 (tr) 2002-02-21
WO2000045810A1 (en) 2000-08-10
JP2002536326A (ja) 2002-10-29

Similar Documents

Publication Publication Date Title
EP1138329B1 (en) Composition containing 5-Methyl-1-phenyl-2-(1 H)-pyridone for reparation and prevention of fibrotic lesions
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CR6458A (es) Composiciones de valdecoxib
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
DE69331409D1 (de) Oral 1alpha-hydroxyprevitamin d
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
AR020803A1 (es) Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento
WO2002042462A3 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
AR037255A1 (es) Composiciones farmaceuticas que contienen oxibutinina
BR9916860A (pt) Método de reduzir colesterol do sangue e/outriglicerìdios do sangue em um indivìduo mamìfero,preparação em forma de unidade de dosagem, e,conjunto para administrar oralmente a mesma
AR008392A1 (es) Procedimiento que utiliza una porfirina verde para preparar un medicamento para prevenir o inhibir la formacion de placas arteriales y la composicionfarmaceutca obtenida por dicho procedimiento
AR015744A1 (es) Uso de dexmedetomidina para sedacion en terapia intensiva
ATE311928T1 (de) (-)-pseudoephedrin als sympathomimetisches arzneimittel
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
CO5160246A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
AR025549A1 (es) Mofetil micofelonato en asociacion con peg-ifn-alfa
AR012638A1 (es) Uso de pregnan-3-ol-20-onas para la manufactura de un medicamento util para proveer una terapia progestacional
CO5150206A1 (es) Metodo para la prevencion o reduccion de episodios cardiovasculares asociados con intervenciones coronarias
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
SE8804640L (sv) Laekemedel omfattande cyklolinopeptide a
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
AU4918900A (en) Interferon-beta use in the treatment of ewing's family of tumors
ITRM20010695A1 (it) Uso della propionil l-carnitina o di un suo sale farmacologicamente accettabile per la preparazione di un medicamento per il trattamento del